Genfit SA
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more
Genfit SA (GNFTF) - Total Assets
Latest total assets as of June 2025: $216.68 Million USD
Based on the latest financial reports, Genfit SA (GNFTF) holds total assets worth $216.68 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genfit SA - Total Assets Trend (2004–2024)
This chart illustrates how Genfit SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genfit SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Genfit SA's total assets of $216.68 Million consist of 61.3% current assets and 38.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.0% |
| Accounts Receivable | $7.56 Million | 5.0% |
| Inventory | $4.00K | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $48.00 Million | 31.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Genfit SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genfit SA's current assets represent 61.3% of total assets in 2024, an increase from 54.8% in 2004.
- Cash Position: Cash and equivalents constituted 54.0% of total assets in 2024, up from 1.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 31.7% of total assets.
Genfit SA Competitors by Total Assets
Key competitors of Genfit SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genfit SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Genfit SA generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Genfit SA generates $ 1.00 in net profit.
Genfit SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.74 | 3.74 | 5.71 |
| Quick Ratio | 3.74 | 3.74 | 5.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $113.85 Million | $ 99.95 Million | $ 196.50 Million |
Genfit SA - Advanced Valuation Insights
This section examines the relationship between Genfit SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.43 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | -12.9% |
| Total Assets | $151.42 Million |
| Market Capitalization | $144.56 Million USD |
Valuation Analysis
Near Book Valuation: The market values Genfit SA's assets close to their book value ( 0.95x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Genfit SA's assets decreased by 12.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genfit SA (2004–2024)
The table below shows the annual total assets of Genfit SA from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $151.42 Million | -12.91% |
| 2023-12-31 | $173.87 Million | -19.33% |
| 2022-12-31 | $215.54 Million | -23.49% |
| 2021-12-31 | $281.72 Million | +41.84% |
| 2020-12-31 | $198.61 Million | -35.90% |
| 2019-12-31 | $309.85 Million | +35.03% |
| 2018-12-31 | $229.48 Million | -21.73% |
| 2017-12-31 | $293.18 Million | +76.39% |
| 2016-12-31 | $166.21 Million | +139.99% |
| 2015-12-31 | $69.26 Million | -19.81% |
| 2014-12-31 | $86.37 Million | +196.27% |
| 2013-12-31 | $29.15 Million | +23.62% |
| 2012-12-31 | $23.58 Million | -18.90% |
| 2011-12-31 | $29.08 Million | -7.36% |
| 2010-12-31 | $31.39 Million | -18.32% |
| 2009-12-31 | $38.43 Million | -16.45% |
| 2008-12-31 | $45.99 Million | +14.37% |
| 2007-12-31 | $40.21 Million | -13.04% |
| 2006-12-31 | $46.24 Million | +49.98% |
| 2005-12-31 | $30.83 Million | +0.75% |
| 2004-12-31 | $30.61 Million | -- |